rofecoxib

mitochondrially encoded cytochrome c oxidase II ; Homo sapiens







262 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
151 12668898 Prevention and treatment of reactions to NSAIDs. 2003 Apr 1
152 12705064 Selective COX-2 inhibitors: a health economic perspective. 2003 1
153 12723742 Relative efficacy of selective COX-2 inhibitors compared with over-the-counter ibuprofen. 2003 Apr 1
154 12723745 Risk factors associated with the development of gastroduodenal ulcers due to the use of NSAIDs. 2003 Apr 1
155 12740337 Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. 2003 Jun 1
156 12749519 A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population. 2003 Feb 1
157 12782016 The role of COX-2 in angiogenesis and rheumatoid arthritis. 2003 Jun 1
158 12783912 Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. 2003 Jun 4 1
159 12816152 Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib. Results of oral provocation tests in patients with NSAID hypersensitivity. 2003 1
160 12818939 An evaluation of the safety and efficacy of administering rofecoxib for postoperative pain management. 2003 Jul 1
161 12845388 Effects of renal insufficiency and hemodialysis on the pharmacokinetics of rofecoxib. 2003 Jul-Aug 2
162 12859668 Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia. 2003 Aug 3
163 12868201 [Coxibs: highly selective cyclooxygenase-2 inhibitors. Part II. Side effects]. 2003 Apr 1
164 12890715 Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin. 2003 Aug 1
165 12902855 COX-2 inhibitors and cancer therapeutics: potential roles for inhibitors of COX-2 in combination with cytotoxic therapy: reports from a symposium held in conjunction with the Radiation Therapy Oncology Group June 2001 Meeting. 2003 Aug 2
166 12906745 Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. 2003 Jul 1
167 12910695 [The effects of selective cyclooxygenase-2 inhibitors on the growth of gastric adenocarcinoma]. 2003 Jul 1
168 12941996 Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials. 2003 May 1 1
169 12975714 A retrospective review of the effect of COX-2 inhibitors on blood pressure change. 2003 Sep-Oct 1
170 14504873 A comparative study of the effect of rofecoxib (a COX 2 inhibitor) and naproxen sodium on analgesic requirements after abdominal hysterectomy. 2003 Oct 1
171 14524083 [Selective COX 2 inhibitor rofecoxib. To "defy" the pain]. 2003 Aug 7 1
172 14530224 Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. 2003 Oct 7 1
173 14552704 Clinical pharmacology of selective COX-2 inhibitors. 2003 May-Aug 1
174 14585914 Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec. 2003 Nov 1
175 14592550 Obligatory role of lipid mediators in platelet-neutrophil adhesion. 2003 Jun 15 1
176 14627347 Rofecoxib reduces polyp recurrence in familial polyposis. 2003 Oct 1
177 14655004 [Clinical pharmacology of the selective COX-2 inhibitors]. 2003 Dec 1
178 15071803 High performance liquid chromatographic determination of cox-2 inhibitor rofecoxib in human plasma. 2003 Aug 1
179 15199473 Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. 2003 May 2
180 11866383 A rapid and sensitive high-performance liquid chromatography assay for rofecoxib in human serum. 2002 Jan 1
181 11898894 Gastrointestinal bleeds associated with rofecoxib. 2002 Mar 1
182 11909557 Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. 2002 Mar 21 1
183 11940070 Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. 2002 Mar 1
184 11945113 Cyclo-oxygenase-2 inhibitors and the kidney: a case for caution. 2002 1
185 11992745 Renal effects of cyclooxygyenase-2-selective inhibitors. 2002 Apr 1
186 12017215 A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. 2002 1
187 12065343 Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. 2002 Jun 1
188 12086291 Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors. 2002 1
189 12100094 Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. 2002 May 1
190 12113843 Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet. 2002 May 1
191 12126328 What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). 2002 Jun 25 2
192 12141411 Successful treatment by cyclooxyenase-2 inhibitor of refractory hypokalemia in a patient with Gitelman's syndrome. 2002 Jul 1
193 12198983 Selecting new drugs for pain control: evidence-based decisions or clinical impressions? 2002 Aug 1
194 12204486 The impact of pain management on quality of life. 2002 Jul 1
195 12217369 Isomeric acetoxy analogues of rofecoxib: a novel class of highly potent and selective cyclooxygenase-2 inhibitors. 2002 Oct 7 2
196 12220285 Rofecoxib-induced instant aquagenic wrinkling of the palms. 2002 Jul-Aug 1
197 12389882 Cyclooxygenase-2 inhibitor-associated acute renal failure: case report with rofecoxib and review of the literature. 2002 Oct 1
198 12395741 [Anti-inflammatory non-steroidal selective cyclooxygenase 2 inhibitors and gastroduodenal lesions]. 2002 Sep 28 1
199 12406411 [Economic evaluation of a new selective COX-2 NSAID, rofecoxib, in a real practice context]. 2002 Oct 31 1
200 12410658 Factor-sparing use of the COX-2 inhibitor rofecoxib in haemophilic arthropathy. 2002 Nov 1